317356-45-9

Upstream product

• 317356-44-8 ethyl 4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetate 
• 1197-55-3 4-aminophenylacetic acid 
• 2285-12-3 o-trifluoromethyl-phenylisocyanate 

Downstream Products

• 1016274-46-6 methyl 3-[2-hydroxy-5-(2-{4-[3-(2-trifluoromethyl-phenyl)-ureido]-phenyl}-acetylamino)-phenyl]-propionate 
• 1016274-49-9 C₂₇H₃₅F₃N₄O₆ 

Relevant academic research and scientific papers

A graftable LDV peptidomimetic: Design, synthesis and application to a blood filtration membrane

A graftable LDV (Leu-Asp-Val) peptidomimetic molecule (B-c) has been prepared from 3-(5-amino-2-hydroxy)phenyl-propionic acid, as α4β1 (VLA-4) integrin ligand. For that purpose, the mechanism of 3-(4-azidophenyl)propionic acid rearrangement has been revisited. Activation of Durapore DVPP-hydrophilic membrane, by surface wet chemistry using triazine trifluoride, followed by covalent coupling of B-c produced a modified filter (0.8% of derivatisation from XPS analysis) with improved capacity of leukocyte retention.

VLA-4 inhibitor compounds

Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.